Results 11 to 20 of about 1,204,710 (358)

Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive Prostate Cancer [PDF]

Journal of Clinical Oncology
PURPOSE Despite major increases in the longevity of men with metastatic hormone-sensitive prostate cancer (mHSPC), most men still die of prostate cancer. Phase III trials assessing new therapies in mHSPC with overall survival (OS) as the primary end point will take approximately a decade to complete.
Susan Halabi, Akash Roy, Larysa Rydzewska, Siyuan Guo, Peter Godolphin, Maha Hussain, Catherine Tangen, Ian Thompson, Wanling Xie, Michael A. Carducci, Matthew R. Smith, Michael J. Morris, Gwenaelle Gravis, David P. Dearnaley, Paul Verhagen, Takayuki Goto, Nick James, Marc E. Buyse, Jayne F. Tierney, Christopher Sweeney   +19 more
openaire   +5 more sources

Clinical Characteristics, Course, and Long-Term Outcomes in Patients with Talaromyces marneffei Infection: A 10-Year Retrospective Cohort Study

Infectious Diseases and Therapy, 2023
Introduction Talaromyces marneffei (T. marneffei), a dimorphic fungus, causes local or disseminated infection in humans. We aimed to analyze the clinical characteristics, prognostic factors, and survival outcomes of patients with T.
QingLiang Yu, Meifang Wei, Rong Xiao, Xiaona Liang, Siqiao Liang, Nan Ma, Siyao Wu, Yan Ning, Jingmin Deng, Meiling Yang, Quanfang Chen, Wen Zeng, Meihua Li, Xiaokai Feng, Zhiyi He   +14 more
doaj   +1 more source

Efficacy and Safety Evaluation of Sintilimab for Cancer Treatment: A Systematic Review and Meta-analysis of Randomized Controlled Trials

Frontiers in Pharmacology, 2022
Objective: Meta analysis was used to explore the efficacy and safety of Sintilimab in the treatment of cancer.Methods: The databases of CNKI, VIP, Wanfang Data, PubMed, ScienceDirect, the Cochrane Library and EMBASE were searched by computer to collect ...
Ziqi Ye, Wenchao Yang, Bixia Xuan, Xiaofang Li, Jiana He, Haiyan Si, Wenhua Ma   +6 more
doaj   +1 more source

Adjuvant radiotherapy improves progression-free survival in intracranial atypical meningioma [PDF]

, 2019
BACKGROUND: Meningiomas are the most common primary tumors of the central nervous system. In patients with WHO grade I meningiomas no adjuvant therapy is recommended after resection.
Acker, Güliz, Badakhshi, Harun, Budach, Volker, Ghadjar, Pirus, Grün, Arne, Hemmati, Saman Moritz, Kaul, David, Misch, Martin, Senger, Carolin, Zschaeck, Sebastian   +9 more
core   +1 more source

Prognostic factors and survival study in high-grade glioma in a hospital in Lima, Peru

Revista de la Facultad de Medicina Humana, 2020
Introduction: Gliomas are primary tumors of the central nervous system. They are classifiedfrom grade I-IV, with high grade III and IV being the most frequent and with poor prognosis. Objective: To determine the prognostic factors of survival in patients
Paul Méndez-Aguilar, Victor Juan Vera-Ponce   +1 more
doaj   +1 more source

Population Pharmacokinetics of Palbociclib and Its Correlation with Clinical Efficacy and Safety in Patients with Advanced Breast Cancer

Pharmaceutics, 2022
Neutropenia is the most frequent dose-limiting toxicity reported in patients with metastatic breast cancer receiving palbociclib. The objective of this study was to investigate the pharmacokinetic–pharmacodynamic (PK/PD) relationships for toxicity (i.e.,
Perrine Courlet, Evelina Cardoso, Carole Bandiera, Athina Stravodimou, Jean-Philippe Zurcher, Haithem Chtioui, Isabella Locatelli, Laurent Arthur Decosterd, Léa Darnaud, Benoit Blanchet, Jérôme Alexandre, Anna Dorothea Wagner, Khalil Zaman, Marie Paule Schneider, Monia Guidi, Chantal Csajka   +15 more
doaj   +1 more source

Conversion of a gastric band into an intraperitoneal port in a patient with optimally debulked stage 3C serous ovarian carcinoma [PDF]

, 2015
Intraperitoneal (IP) chemotherapy in women with optimally debulked stage 3 ovarian cancer improves overall survival and progression-free survival, and its use has been encouraged in the adjuvant treatment of appropriately selected patients (Armstrong et ...
Cohen, P, Tan, J, Tan, J, Tucker, P
core   +2 more sources

Bevacizumab plus Irinotecan-Based Regimens in the Treatment of Metastatic Colorectal Cancer [PDF]

, 2010
Objectives: Bevacizumab is a monoclonal antibody that directly inhibits vascular endothelial growth factor, a key regulator of angiogenesis. Bevacizumab significantly improves progression-free and/or overall survival in metastatic colorectal cancer in ...
Heinemann, Volker, Hoff, Paulo M.
core   +1 more source

Outcome of Primary CNS Lymphoma; A Retrospective Analysis

Asian Pacific Journal of Cancer Care, 2022
Background: Rituximab along with high dose Methotrexate is nowadays the standard of care in treatment of PCNSL. We report the retrospective analysis of PCNSL patients who were treated with and without Rituximab at Aga Khan University Hospital, Karachi ...
Mehwish Shahzadi, Daniyaal Ahmed, Sobia Sawani, Munira Moosajee   +3 more
doaj   +1 more source

The cost-effectiveness of nivolumab monotherapy for the treatment of advanced melanoma patients in England [PDF]

, 2018
Background: Nivolumab was the first programmed death receptor 1 (PD-1) immune checkpoint inhibitor to demonstrate long-term survival benefit in a clinical trial setting for advanced melanoma patients.
Ellis, John, Hertel, Nadine, Johnson, Helen, Lee, Dawn, Meng, Yang, Morais, Edith, Philips, Zoe, Roskell, Neil, Walker, Andrew   +8 more
core   +1 more source